FDA Approves Orzeyful for Narcolepsy Type 1
Orzeyful is the first drug to target the underlying loss of orexin signaling to address the full range of narcolepsy type 1.
Category: Products & Treatment
Products & Treatment
Latest
Products & Treatment
Latest
5 Tips for Back-to-School Allergy Management
The American College of Allergy, Asthma, and Immunology (ACAAI) outlines essential steps for families and school staff to navigate seasonal allergy triggers and respiratory health.
Products & Treatment
Latest
Capnography and Pulse Oximetry in the PICU
For patients in the pediatric ICU, pulse oximetry and waveform capnography are valuable tools to monitor the effectiveness of respiratory support and to inform treatment decisions.
Industry & Regulatory News
Latest
ProAxsis Transitions to Independent Growth Company to Advance Respiratory Research
A new fundraise will support commercial scale-up and the development of biomarker technology for respiratory disease drug development.
Pharmaceuticals
Latest
Experimental Monoclonal Antibody Improved ARDS Outcomes
A proof-of-concept study showed an experimental monoclonal antibody targeting ARDS inflammation increased ventilator-free days and reduced organ failure.
Diagnostics & Testing
Latest
Plasma Tests for Fungal Infections and Pneumonia
Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii and the FungiFlex Mold Plus Panel testing assays.
Monitoring & Treatment
Latest
Voice Changes May Help Monitor Asthma and COPD at Home
New research suggests acoustic speech features can identify respiratory exacerbations from the first day of onset.